New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

My recommendation is to begin with first principles by thoroughly understanding the core job your customer needs to ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay ...

Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei ...

SAN JOSE, Antique (PIA) — The municipality of Tobias Fornier recently activated its Barangay Information Officers (BIO) ...

Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement.